Anne Kreklau1, Ivonne Nel2, Sabine Kasimir-Bauer3, Rainer Kimmig3, Anna Christina Frackenpohl3, Bahriye Aktas2,3. 1. Department of Gynecology and Obstetrics, University Hospital Leipzig, Leipzig, Germany; anne.kreklau@medizin.uni-leipzig.de. 2. Department of Gynecology and Obstetrics, University Hospital Leipzig, Leipzig, Germany. 3. Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany.
Abstract
BACKGROUND/AIM: Breast cancer survivors are increasingly interested in lifestyle modifications in order to reduce the risk of recurrence and mortality. Therefore, we aimed to study the association between survival and lifestyle related risk factors such as obesity, alcohol intake, smoking, medication and atopic diseases. PATIENTS AND METHODS: In this observational single center study, clinicopathological parameters of 635 women with primary breast cancer were sampled. A logistic regression model was applied to investigate correlations among clinical data and various life style related factors. Patients were stratified according to lifestyle and treatment characteristics. Cox regression and the Kaplan-Meier method were used to analyze survival differences in various patient subsets and to identify possible prognostic factors. RESULTS: Logistic regression analysis indicated a correlation between low Body Mass Index (BMI) and extended progression-free survival (PFS). Cox regression showed that patients not using beta-blockers had a significantly prolonged overall survival (OS) compared to beta-blocker users [hazard ratio (HR)=3.7; 95% confidence interval (CI)=1.66-8.14, p=0.01]. Apparently, the clincopathological parameters including BMI, HER2-, estrogen receptor (ER) and progesteron receptor (PR)-status as well as treatment with chemo-, radio- and endocrine therapy did not play a role regarding the survival differences between beta-blocker users and non-users. CONCLUSION: Patients not using beta-blockers appeared to benefit from extended PFS and OS. Further, patients with a rather low BMI (<30 kg/m2) seemed to have a survival benefit compared to obese patients. Particularly, among postmenopausal women, beta-blocker intake and obesity appeared to be possible life style related prognostic factors that could be used for patient stratification. Copyright
BACKGROUND/AIM: Breast cancer survivors are increasingly interested in lifestyle modifications in order to reduce the risk of recurrence and mortality. Therefore, we aimed to study the association between survival and lifestyle related risk factors such as obesity, alcohol intake, smoking, medication and atopic diseases. PATIENTS AND METHODS: In this observational single center study, clinicopathological parameters of 635 women with primary breast cancer were sampled. A logistic regression model was applied to investigate correlations among clinical data and various life style related factors. Patients were stratified according to lifestyle and treatment characteristics. Cox regression and the Kaplan-Meier method were used to analyze survival differences in various patient subsets and to identify possible prognostic factors. RESULTS: Logistic regression analysis indicated a correlation between low Body Mass Index (BMI) and extended progression-free survival (PFS). Cox regression showed that patients not using beta-blockers had a significantly prolonged overall survival (OS) compared to beta-blocker users [hazard ratio (HR)=3.7; 95% confidence interval (CI)=1.66-8.14, p=0.01]. Apparently, the clincopathological parameters including BMI, HER2-, estrogen receptor (ER) and progesteron receptor (PR)-status as well as treatment with chemo-, radio- and endocrine therapy did not play a role regarding the survival differences between beta-blocker users and non-users. CONCLUSION:Patients not using beta-blockers appeared to benefit from extended PFS and OS. Further, patients with a rather low BMI (<30 kg/m2) seemed to have a survival benefit compared to obesepatients. Particularly, among postmenopausal women, beta-blocker intake and obesity appeared to be possible life style related prognostic factors that could be used for patient stratification. Copyright
Authors: Thomas I Barron; Roisin M Connolly; Linda Sharp; Kathleen Bennett; Kala Visvanathan Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Patricia A Ganz; Laurel A Habel; Erin K Weltzien; Bette J Caan; Steven W Cole Journal: Breast Cancer Res Treat Date: 2011-04-11 Impact factor: 4.872
Authors: Cheryl L Rock; Shirley W Flatt; Tim E Byers; Graham A Colditz; Wendy Demark-Wahnefried; Patricia A Ganz; Kathleen Y Wolin; Anthony Elias; Helen Krontiras; Jingxia Liu; Michael Naughton; Bilgé Pakiz; Barbara A Parker; Rebecca L Sedjo; Holly Wyatt Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Huiyan Ma; Giske Ursin; Xinxin Xu; Eunjung Lee; Kayo Togawa; Kathleen E Malone; Polly A Marchbanks; Jill A McDonald; Michael S Simon; Suzanne G Folger; Yani Lu; Jane Sullivan-Halley; Dennis M Deapen; Michael F Press; Leslie Bernstein Journal: Breast Cancer Res Date: 2018-01-22 Impact factor: 6.466
Authors: Manuel Picon-Ruiz; Cynthia Morata-Tarifa; Janeiro J Valle-Goffin; Eitan R Friedman; Joyce M Slingerland Journal: CA Cancer J Clin Date: 2017-08-01 Impact factor: 508.702
Authors: Minouk J Schoemaker; Hazel B Nichols; Lauren B Wright; Mark N Brook; Michael E Jones; Katie M O'Brien; Hans-Olov Adami; Laura Baglietto; Leslie Bernstein; Kimberly A Bertrand; Marie-Christine Boutron-Ruault; Tonje Braaten; Yu Chen; Avonne E Connor; Miren Dorronsoro; Laure Dossus; A Heather Eliassen; Graham G Giles; Susan E Hankinson; Rudolf Kaaks; Timothy J Key; Victoria A Kirsh; Cari M Kitahara; Woon-Puay Koh; Susanna C Larsson; Martha S Linet; Huiyan Ma; Giovanna Masala; Melissa A Merritt; Roger L Milne; Kim Overvad; Kotaro Ozasa; Julie R Palmer; Petra H Peeters; Elio Riboli; Thomas E Rohan; Atsuko Sadakane; Malin Sund; Rulla M Tamimi; Antonia Trichopoulou; Giske Ursin; Lars Vatten; Kala Visvanathan; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Dale P Sandler; Anthony J Swerdlow Journal: JAMA Oncol Date: 2018-11-08 Impact factor: 31.777